Document:

TherapeuticsMD 8-K

 

Exhibit 10.1

 

 

THERAPEUTICSMD, INC.

NOTE PURCHASE AGREEMENT

This Note Purchase Agreement
(this “Agreement”) is made by and among TherapeuticsMD, Inc., a Nevada corporation (the “Company”),
and each of Plato & Associates, Inc., a Missouri limited liability company and Steven Johnson, a resident of Texas (collectively
known as the “Purchasers” or individually as each "Purchaser").

		1.	The Notes and Warrants. 

1.1  
Authorization of the Notes and Warrants. The Company has authorized the sale and issuance
of secured promissory notes (the “Notes”) in the aggregate amount of $4,691,847.32 and cashless common stock
purchase warrants (the “Warrants”) to purchase an aggregate of 7,000,000 shares of the Company's Common Stock
(the “Shares”). The Notes shall be substantially in the form attached hereto as Exhibit A and the
Warrants shall be substantially in the form attached hereto as Exhibit B. 

1.2  
Purchase and Sale of the Notes and Warrants. 

(a)   
Purchase and Sales of Notes and Warrants. 

                                                                                    
(i)         
Purchase of Notes. Each Purchaser agrees to purchase, and the Company agrees
to, severally and not jointly, sell and issue to each Purchaser, a Note in the principal amount set forth opposite each Purchaser's
name on the signature page attached hereto. The Notes shall be due on February 24, 2014 (the "Maturity Date"). 

                                                                                  
(ii)         
Purchase Price. The purchase price for the Notes and Warrants to be purchased
by the Purchasers hereunder shall be set forth on Schedule I attached hereto (the "Purchase Price"). 

 

                                                                                
(iii)         
Purchase of Warrants. As an inducement for the Purchasers to lend additional
funds to the Company as outlined herein on Schedule I, the Purchasers, and/or assigns, will receive Warrants to purchase an aggregate
of 7,000,000 Shares. Each Purchaser will receive one Warrant for the purchase of 3,000,000 shares with an exercise price of $2.00
per share and one Warrant for the purchase of 500,000 shares with an exercise price of $3.00 per share. The Warrants shall terminate
on the date that is five (5) years from the date of the issuance of the Notes; however, the Warrants may not be exercised until
ninety (90) days after issuance.

 

                                                                                 
(iv)         
Security. In order to induce each Purchaser to extend the credit evidenced by
the Notes, the Company has agreed to enter into a Security Agreement of even date herewith and to grant Collateral Agent, for the
benefit of itself and the Purchasers, the security interest in the Collateral described in the Security Agreement in the form attached
hereto as Exhibit C.

                                                                                  
(v)         
Closing. The purchase and sale of the Notes and Warrants shall take place at
the offices of the Company at such time and place as the Company and the Purchasers shall mutually agree upon, orally or in writing.

(b)  
Form of Payment. At Closing, each Purchaser shall pay the respective Purchase
Price to the Company by check payable to the Company or by wire transfer of immediately available funds (or any combination thereof),
and the Company shall deliver to each Purchaser a Note in a principal amount equal to the respective Purchase Price, together with
such Warrants issued per the Purchaser's instructions.

     

     

    

This Agreement,
the Notes, the Warrants, Security Agreement and the other documents delivered in connection with this Agreement, are referred to
hereinafter as the “Transaction Documents”).

2.               
Representations and Warranties of the Company. The
Company hereby represents and warrants to the Purchasers as follows:

2.1  
Organization and Standing.  The Company is a Nevada corporation duly organized
and validly existing under, and by virtue of, the laws of the State of Nevada and is in good standing under such laws. 

2.2  
Power.  The Company has all requisite legal power and authority (i) to own and
operate its properties and assets and to carry on its business, (ii) to execute and deliver the Transaction Documents, (iii) to
sell and issue the Notes and Warrants and (iv) to carry out and perform the provisions of the Transaction Documents.

2.3  
Authorization.  All necessary action on the part of the Company, its officers,
and directors necessary for the authorization, execution, and delivery of the Transaction Documents, the performance of all obligations
of the Company hereunder and thereunder, and the authorization, issuance, sale and delivery of the Notes and Warrants have been
taken or will be taken at or prior to the Closing. This Agreement constitutes, and each Note and Warrant, when executed and delivered
by the Company, will constitute valid and binding obligations of the Company, enforceable in accordance with their respective terms,
except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies.

3.               
Representations and Warranties of the PURCHASERs.  Each
Purchaser hereby represents and warrants to the Company, severally and not jointly, as of the applicable closing date, as follows:

3.1  
Binding Obligation.  All action on the part of the Purchaser for the authorization,
execution, delivery and performance by the Purchaser of this Agreement has been taken, and this Agreement constitutes a valid and
binding obligation of the Purchaser, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally
and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

3.2  
Accredited Investor.  The Purchaser is an accredited investor within the meaning
of Rule 501 of Regulation D prescribed by the Securities and Exchange Commission pursuant to the Securities Act. If other
than an individual, the Purchaser also represents the Purchaser has not been organized for the specific purpose of acquiring the
Note(s).

3.3  
Investment Experience.  The Purchaser acknowledges that he is able to fend for
himself, can bear the economic risk of its investment and has such knowledge and experience in financial or business matters that
he is capable of evaluating the merits and risks of the investment in the Underlying Securities.

3.4  
Investment Intent.  The Purchaser is acquiring the Note for investment for the
Purchaser’s own account and not with a view to, or for resale in connection with, any distribution thereof. The Purchaser
understands that the neither the Note or the Shares have been registered under the Securities Act by reason of a specific exemption
from the registration provisions of the Securities Act that depends upon, among other things, the bona fide nature of the investment
intent as expressed herein.

     

     

    
3.5  
Rule 144.  The Purchaser acknowledges that the Note and Warrant(s), and upon
exercise of the Warrant(s), the Shares, must be held until subsequently registered under the Securities Act or unless an exemption
from such registration is available. The Purchaser is aware of the provisions of Rule 144 promulgated under the Securities
Act which permits limited resale of securities purchased in a private placement subject to the satisfaction of certain conditions.

3.6  
Information.  The Purchaser believes he has received all the information he considers
necessary or appropriate for deciding whether to purchase the Note and Warrant(s). The Purchaser further represents that such Purchaser
has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the Note and
Warrant(s) and the business, properties, prospects and financial condition of the Company.

4.               
Miscellaneous. 

4.1  
Waivers and Amendments.  This Agreement and the obligations of the Company and
the rights of the Purchasers under this Agreement, the Notes and Warrants may be amended, waived, discharged or terminated (either
generally or in a particular instance, either retroactively or prospectively and either for a specified period of time or indefinitely)
with the written consent of the Company and the Purchasers.

4.2  
Governing Law; Venue.  This agreement shall be governed in all respects by the
laws of the State of Nevada. Each of the parties hereto hereby consents to the exclusive jurisdiction of: (i) any state courts
of the state of Florida and (ii) any federal court located in the state of Florida, as well as to the jurisdiction of all courts
to which an appeal may be taken from such courts, for the purpose of any suit, action or other proceeding arising out of, or in
connection with, this agreement or any of the transactions contemplated hereby. Each party hereby expressly waives any and all
rights to bring any suit, action or other proceeding in or before any court or tribunal other than those located in the state of
Florida. In addition, each of the parties consent to the service of process by personal service or any manner in which notices
may be delivered hereunder in accordance with this agreement. 

4.3  
Notices.  All notices and other communications required or permitted under this
Agreement shall be in writing and shall be delivered personally by hand or by courier, mailed by United States first-class mail,
postage prepaid, sent by facsimile or sent by electronic mail directed (a) if to a Purchaser, at such Purchaser’s address,
facsimile number or electronic mail address set forth on Schedule A hereto, or at such other address, facsimile number or
electronic mail address as such Purchaser may designate by ten (10) days’ advance written notice to the Company or (b) if
to the Company, to its address, facsimile number or electronic mail set forth on its signature page to this Agreement and directed
to the attention of the Chief Executive Officer, or at such other address, facsimile number or electronic mail as the Company may
designate by ten (10) days’ advance written notice to the Purchasers. All such notices and other communications shall be
effective or deemed given upon personal delivery, on the date of mailing, upon confirmation of facsimile transfer or upon delivery
to electronic mail address set forth on Schedule A hereto opposite the recipient’s name. 

4.4  
Purchasers Acting Independently. Each Purchaser enters into this Agreement independently
of the other Purchaser and has negotiated separately with the Company. The Purchasers should not be treated as a single group. 

     

     

    
4.5  
 Entire Agreement.  This Agreement (including the schedules and exhibits attached
hereto) and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the
parties with regard to the subjects hereof and thereof.

4.6  
Severability.  If one or more provisions of this Agreement are held to be unenforceable
under applicable law, such provision(s) shall be excluded from this Agreement and the balance of this Agreement shall be interpreted
as if such provision(s) were so excluded and shall be enforceable in accordance with its terms.

4.7  
Successors and Assigns.  Except as otherwise expressly provided in this Agreement
or the Notes, the provisions of this Agreement and the Notes shall inure to the benefit of, and be binding upon, the successors,
assigns, heirs, executors and administrators of the parties hereto.

4.8  
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing
to the Investor, upon any breach or default of the Company under this Agreement shall impair any such right, power, or remedy of
the Investor nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any
similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any
other breach or default therefore or thereafter occurring. All remedies, either under this Agreement or by law or otherwise afforded
to the Investors, shall be cumulative and not alternative.

4.9  
Titles and Subtitles.  The titles of the paragraphs and subparagraphs of this
Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

4.10         
Telecopy Execution and Delivery.  A facsimile, telecopy or other reproduction
of this Agreement may be executed by one or more parties hereto, and an executed copy of this Agreement may be delivered by one
or more parties hereto by facsimile or similar electronic transmission device pursuant to which the signature of or on behalf of
such party can be seen, and such execution and delivery shall be considered valid, binding and effective for all purposes. At the
request of any party hereto, all parties hereto agree to execute an original of this Agreement as well as any facsimile, telecopy
or other reproduction hereof.

4.11         
Counterparts.  This Agreement may be executed in any number of counterparts, each
of which shall be an original, but all of which together shall be deemed to constitute one instrument.

4.12         
Construction.  The language used in this Agreement and the Notes will be deemed
to be the language chosen by the parties to express their mutual intent and no rules of strict construction will be applied against
any party.

4.13         
Other Interpretive Provisions. References in this Agreement and each of the other Transaction
Documents to any document, instrument or agreement (a) includes all exhibits, schedules and other attachments thereto, (b) includes
all documents, instruments or agreements issued or executed in replacement thereof, and (c) means such document, instrument
or agreement, or replacement or predecessor thereto, as amended, modified and supplemented from time to time and in effect at any
given time. The words “hereof,” “herein” and “hereunder” and words of similar import when used
in this Agreement or any other Transaction Document refer to this Agreement or such other Transaction Document, as the case may
be, as a whole and not to any particular provision of this Agreement or such other Transaction Document, as the case may be. The
words “include” and “including” and words of similar import when used in this Agreement or any other Transaction
Document shall not be construed to be limiting or exclusive.

     

     

    

4.14         
Termination of Notes Upon Payment. Upon payment in full of any Note outstanding issued
pursuant to this Agreement, such Note shall automatically be terminated and the Company shall be forever released from any and
all of its obligations and liabilities under each such Note. 

 

IN WITNESS WHEREOF, the
parties have executed this Agreement on the day, month and year below.

 

	
         

        Dated:
        June 19, 2012
	
        THERAPEUTICSMD,
        INC.

         

        By: /s/ Robert
        Finizio________________________

        Robert Finizio

        Chief Executive Officer

        Address:

        TherapeuticsMD,
        Inc.

        951 Broken Sound
        Parkway NW, #320

        Boca Raton, FL 33487

 

 

     

     

    

Purchasers:

 

	
        Principal Amount
        of Note: $2,347,128.06

         

         

        Dated:
        June 19, 2012

         
	
        STEVEN
        JOHNSON

         

         

        By: /s/ Steven
        Johnson_________________

        Steven Johnson, an individual

        Address:

        804
        Tree Haven Court

        Highland
        Village, TX 75077

        E-Mail:
        worksteve@aol.com

 

 

	
        Principal Amount
        of Note: $2,344,719.26

         

        Dated:
        June 19, 2012

         
	
        PLATO
        & ASSOCIATES, LLC

         

         

        By:
        /s/ Robert J, Smuth___________________

        Robert J. Smith, Sole Member

        Address:

        13652
        Fiddlesticks Blvd.

        Suite
        202-324

        ft.
        myers, fl 33912

        E-Mail:
        rjsmith@usa.com 

 

 

 

     

     

    

SCHEDULE I

 

PURCHASE PRICE FOR NOTES AND WARRANTS

 

 

Steven Johnson

 

Purchase Price is $2,347,128.06 paid as follows:

 

(a)     
Cash in the amount of $1,000,000

		(b)	Exchange of principle of $1,347,128.06 under a note dated February 24, 2012 

 

 

Plato & Associates, LLC

 

Purchase Price is $2,344,719.26 paid as follows:

 

(a)     
Cash in the amount of $1,000,000

		(b)	Exchange of principle of $1,344,719.26 under a note dated February 24, 2012TherapeuticsMD 8-K

 

Exhibit 10.1

  

ThIS
NOTE HAS not been registered under the Securities Act of 1933, as amended, OR THE SECURITIES LAWS OF ANY STATE. it may not be sold,
offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under
such Act AND/OR APPLICABLE STATE SECURITIES LAWS, or an opinion of counsel
satisfactory to the Company that such registration is not required or unless sold pursuant to Rule 144 of such Act.

 

THERAPEUTICSMD,
INC.

SECURED
PROMISSORY NOTE

_______________

	 $__________	  Boca Raton, FL

 

FOR VALUE RECEIVED, upon the terms and subject to the conditions
set forth in this secured promissory note (the "Note"), THERAPEUTICSMD, INC., a Nevada corporation (the “Company”),
absolutely and unconditionally promises to pay to __________________________ (the “Holder”), or registered
assigns, the principal base amount of __________________ (___________) ("Principal Base Amount"), plus any and all additional
advances made to the Company as recorded on Exhibit 1 attached hereto ("Aggregated Principal Amount"), together
with accrued interest as hereinafter provided on the outstanding Aggregated Principal Amount remaining unpaid from time to time.
The Maturity Date is ____________ on which the Aggregated Principal Amount, together with any accrued but unpaid interest and
any other amounts payable hereunder, shall be due and payable. This Note is issued in connection with a certain Note Purchase
Agreement and Security Agreement of even date herewith, between the Company and the Holder, all terms of which are incorporated
herein by this reference and hereby made a part of this Note. Capitalized terms not defined herein shall have the meanings ascribed
to them in the Note Purchase Agreement or Security Agreement.

 

The following is a statement
of the rights of the Holder of this Note and the conditions to which this Note is subject, to which the Holder, by the acceptance
of this Note, agrees:

1.              
Interest. Accrued interest on this Note shall be payable on the Maturity Date of this Note at an interest rate of six
percent (6%) per annum.

2.              
Repayment; Security. Payment of the Aggregated Principal Amount of this Note (and any interest accrued thereon) shall
be made in U.S. dollars in immediately available funds. This Note (including all principal amount outstanding and any unpaid accrued
interest thereunder), may be prepaid at any time without penalty. The obligations of the Company under this Note are secured pursuant
to a security interest on assets, tangible and intangible, of the Company granted by the Company to the Holder pursuant to a Security
Agreement.

     

     

    
3.              
Default; Remedies.

3.1 
Default. The Company shall be in default under this Note upon the happening of any condition or event set forth below
(each, an “Event of Default”):

(a)  
the Company’s failure to pay (i) when due any principal or interest payment on the due date hereunder or (ii) any
other payment required under the terms of this Note on the date due, and such default shall continue unremedied for a period of
15 days following receipt of written notice signed by the Holder of such failure to pay;

(b) 
the Company’s failure to observe or perform in any material respect any other covenant, obligation, condition or agreement
contained in this Note and such failure shall continue for a period of 15 days following receipt of written notice signed by the
Holder of such failure;

(c)  
the Company shall (i) apply for or consent to the appointment of a receiver, trustee, liquidator or custodian of itself
or of all or a substantial part of its property, (ii) be unable, or admit in writing its inability, to pay its debts as they
mature, (iii) make a general assignment for the benefit of its or any of its creditors, (iv) be dissolved or liquidated,
(v) become insolvent (as such term may be defined or interpreted under any applicable statute), (vi) commence a voluntary
case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy,
insolvency or other similar law now or hereafter in effect or consent to any such relief or to the appointment of or taking possession
of its property by any official in an involuntary case or other proceeding commenced against it, or (vii) take any action
for the purpose of effecting any of the foregoing; or

(d) 
proceedings for the appointment of a receiver, trustee, liquidator or custodian of the Company or of all or a substantial
part of the property thereof, or an involuntary case or other proceedings seeking liquidation, reorganization or other relief with
respect to the Company or the debts thereof under any bankruptcy, insolvency or other similar law now or hereafter in effect shall
be commenced and an order for relief entered or such proceeding shall not be dismissed or discharged within 30 days of commencement.

3.2 
Remedies. Upon the occurrence or existence of any Event of Default (other than an Event of Default described in Sections
3.1(c) or 3.1(d)) and at any time thereafter during the continuance of such Event of Default, the Holder may, by written notice
to the Company, declare the entire outstanding Aggregated Principal Amount of this Note, any accrued but unpaid interest and any
other amounts payable under this Note to be immediately due and payable without presentment, demand, protest or any other notice
of any kind, all of which are hereby expressly waived, anything contained herein or in the other Transaction Documents to the contrary
notwithstanding. Upon the occurrence or existence of any Event of Default described in Sections 3.1(c) or 3.1(d) immediately and
without notice, all outstanding Obligations payable by the Company hereunder shall automatically become immediately due and payable,
without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived, anything contained
herein or in the other Transaction Documents to the contrary notwithstanding. In addition to the foregoing remedies, upon the occurrence
or existence of any Event of Default, Investor may exercise any other right power or remedy granted to him by the Transaction Documents
or otherwise permitted to him by law, either by suit in equity or by action at law, or both.

    2

     

    

4.              
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall be a Saturday, a Sunday or a legal holiday, then such action may be taken or such right
may be exercised on the next succeeding day that is not a Saturday, Sunday or legal holiday.

5.              
Cumulative Rights. No delay on the part of the Holder in the exercise of any power or right under this Note or under
any other instrument executed pursuant to this Agreement shall operate as a waiver of any such power or right, nor shall a single
or partial exercise of any power or right preclude other or further exercise of such power or right or the exercise of any other
power or right.

6.              
Miscellaneous.

6.1Loss, Theft,
Destruction or Mutilation of Note. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Note and, in the case of loss, theft or destruction, and delivery of an agreement satisfactory to the Company
to indemnify the Company from any loss incurred by it connection with the Note (without the requirement of a bond) or, in the case
of mutilation, on surrender and cancellation of this Note, the Company shall execute and deliver, in lieu of this Note, a new Note
executed in the same manner as this Note, in the same principal amount as the unpaid principal amount of this Note and dated the
date to which interest shall have been paid on this Note or, if no interest shall have yet been so paid, dated the date of this
Note.

6.2Payment. All
payments under this Note shall be made in lawful tender of the United States.

 

6.3Waivers and Amendments.
This Note and the obligations of the Company and the rights of the Holder under this Note may be amended, waived, discharged or
terminated (either generally or in a particular instance, either retroactively or prospectively and either for a specified period
of time or indefinitely) only with the written consent of the Company and the Holder.

 

6.4Severability.
If one or more provisions of this Note are held to be unenforceable under applicable law, such provision(s) shall be excluded from
this Note and the balance of this Note shall be interpreted as if such provision(s) were so excluded and shall be enforceable in
accordance with its terms.

 

6.5Successors and
Assigns. Subject to compliance with applicable federal and state securities laws, this Note and all rights under this Note
are transferable in whole or in part by the Holder to any person or entity upon written notice to the Company. The transfer shall
be recorded on the books of the Company upon the surrender of this Note, properly endorsed, to the Company at its principal offices,
and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. In the event of a
partial transfer, the Company shall issue to the holders one or more appropriate new notes. Except as otherwise expressly provided
in this Note, the provisions of this Note shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors
and administrators of the Company and the Holder.

    3

     

    

6.6Usury.
The Company does not intend to pay and the Holder does not agree or intend to contract for, charge, collect, take, reserve or receive
(collectively referred to herein as “charge or collect” any amount in the nature of interest which would in any way
or event cause the Holder to charge or collect more for this loan than the maximum the Holder would be permitted to charge or collect
by law. Any such excess interest shall, instead of anything stated to the contrary, be applied first to reduce the principal balance
of this Note, and when the principal has been paid in full, be refunded to the Company.

6.7Delays
or Omissions. No delay or omission to exercise any right, power, or remedy accruing to the Holder, upon any breach or default
of the Company under this Note shall impair any such right, power, or remedy of the Holder nor shall it be construed to be a waiver
of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other breach or default therefore or thereafter occurring.
Any waiver, permit, consent, or approval of any kind or character on the part of the Holder of any breach or default under this
Note or any waiver on the part of the Holder of any provisions or conditions of this Note must be made in writing and shall be
effective only to the extent specifically set forth in such writing. All remedies, either under this Note or by law or otherwise
afforded to the Holder, shall be cumulative and not alternative.

6.8Titles
and Subtitles. The titles of the paragraphs and subparagraphs of this Note are for convenience of reference only and are not
to be considered in construing this Note.

6.9Construction.
The language used in this Note will be deemed to be the language chosen by the parties to express their mutual intent and no rules
of strict construction will be applied against any party.

6.10Governing
Law; Venue. This note shall be governed in all respects by the laws of the state of Nevada. Each of the parties hereto hereby
consents to the exclusive jurisdiction of: (i) any state courts of the state of Florida and (ii) any federal court located in the
state of Florida, as well as to the jurisdiction of all courts to which an appeal may be taken from such courts, for the purpose
of any suit, action or other proceeding arising out of, or in connection with, this agreement or any of the transactions contemplated
hereby. Each party hereby expressly waives any and all rights to bring any suit, action or other proceeding in or before any court
or tribunal other than those located in the state of Florida. In addition, each of the parties consent to the service of process
by personal service or any manner in which notices may be delivered hereunder in accordance with this agreement.

 

[Signature page follows]

    4

     

    

IN WITNESS WHEREOF,
the Company has caused this Note to be executed by its officers thereunto duly authorized.

	 	THERAPEUTICSMD, INC.
	 	 
	 	By: 	
	 	 	Robert F. Finizio
Chief Executive
    Officer

 

    5

     

    

 

EXHIBIT 1

 

SCHEDULE OF ADVANCES UNDER SECURED PROMISSORY
NOTE

 

 

	
         

         

        DATE
	
         

         

        ACTION
	
         

         

        AMOUNT
	
        OUTSTANDING

        PRINCIPAL BALANCE
	
         

        MAKER’S INITIAL

	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]